News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,556 Results
Type
Article (14303)
Company Profile (105)
Press Release (260140)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88508)
Career Advice (466)
Deals (15419)
Drug Delivery (73)
Drug Development (36776)
Employer Resources (50)
FDA (6416)
Job Trends (6235)
News (151079)
Policy (14175)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (446)
Accelerated approval (13)
Adcomms (8)
Allergies (68)
Alliances (23400)
ALS (57)
Alzheimer's disease (479)
Antibody-drug conjugate (ADC) (99)
Approvals (6611)
Artificial intelligence (201)
Autoimmune disease (41)
Automation (12)
Bankruptcy (150)
Best Places to Work (4373)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (39)
Brain cancer (30)
Breast cancer (173)
Cancer (1339)
Cardiovascular disease (151)
Career advice (419)
Career pathing (13)
CAR-T (50)
CDC (6)
Cell therapy (151)
Cervical cancer (9)
Clinical research (32080)
Collaboration (729)
Compensation (326)
Complete response letters (33)
COVID-19 (781)
CRISPR (43)
C-suite (433)
Cystic fibrosis (58)
Data (1837)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1391)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (81)
Earnings (33576)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (39123)
Executive appointments (530)
FDA (7520)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (431)
Gene editing (70)
Generative AI (18)
Gene therapy (167)
GLP-1 (441)
Government (1411)
Grass and pollen (4)
Guidances (164)
Healthcare (3594)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (15)
Indications (53)
Infectious disease (845)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (61)
IPO (5935)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3454)
Liver cancer (22)
Longevity (8)
Lung cancer (185)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1313)
Medtech (1320)
Mergers & acquisitions (9906)
Metabolic disorders (436)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (84)
Neuropsychiatric disorders (37)
Neuroscience (892)
Neurotech (1)
NextGen: Class of 2026 (1591)
Non-profit (609)
Now hiring (17)
Obesity (228)
Opinion (141)
Ovarian cancer (40)
Pain (110)
Pancreatic cancer (52)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (118)
Peanut (13)
People (29789)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8330)
Phase 2 (13543)
Phase 3 (12235)
Pipeline (1917)
Policy (135)
Postmarket research (1402)
Preclinical (3341)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (353)
Real estate (2660)
Recruiting (18)
Regulatory (10998)
Reports (15)
Research institute (579)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (49)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1646)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (32)
Weight loss (141)
Women's health (27)
Worklife (4)
Date
Today (25)
Last 7 days (155)
Last 30 days (683)
Last 365 days (10462)
2026 (980)
2025 (10744)
2024 (12532)
2023 (14294)
2022 (19631)
2021 (20130)
2020 (19121)
2019 (14955)
2018 (11762)
2017 (13917)
2016 (13160)
2015 (15514)
2014 (12444)
2013 (10609)
2012 (11412)
2011 (11933)
2010 (10905)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20896)
Australia (2688)
California (3192)
Canada (1489)
China (552)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40923)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (241)
Iowa (2)
Japan (247)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (423)
Massachusetts (2591)
Michigan (46)
Minnesota (166)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1399)
New Mexico (7)
New York (913)
North Carolina (619)
North Dakota (2)
Northern California (1455)
Ohio (82)
Oklahoma (5)
Oregon (18)
Pennsylvania (717)
Puerto Rico (12)
Rhode Island (17)
South America (511)
South Carolina (10)
Southern California (1391)
Tennessee (53)
Texas (458)
United States (12710)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (224)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
274,556 Results for "intercept pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
·
8 min read
Autoimmune disease
Intercept Withdraws Embattled Liver Drug from US Market
Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval last year after an advisory committee was unable to verify a favorable risk/benefit profile.
September 12, 2025
·
2 min read
·
Tristan Manalac
Adcomms
Intercept’s Ocaliva in Jeopardy as FDA Questions Efficacy, Safety Ahead of Adcomm
With a Friday advisory committee meeting looming, the sole indication for Intercept Pharmaceuticals’ Ocaliva appears to be at risk as the regulator flags issues regarding its post-marketing results.
September 12, 2024
·
2 min read
·
Tristan Manalac
Regulatory
FDA Pushes Back PDUFA Dates for Amgen and Intercept
The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic colorectal cancer and Intercept Pharmaceuticals’ Ocaliva for primary biliary cholangitis.
October 18, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers
November 10, 2025
·
8 min read
Press Releases
Nouscom to Present New Positive Phase 1b/2 Clinical and Translational Data on NOUS-209 Immunogenicity and Cancer Interception Potential in Lynch Syndrome Carriers at SITC 2025
October 31, 2025
·
7 min read
Deals
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
November 8, 2023
·
12 min read
Press Releases
Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
September 12, 2025
·
9 min read
Press Releases
Intercept Announces Data to be Presented at Digestive Disease Week 2025
April 30, 2025
·
15 min read
Drug Development
Intercept Announces New Data to be Presented at the European Association for the Study of the Liver (EASL) Congress 2024
Intercept Pharmaceuticals, Inc. announced nine abstracts related to primary biliary cholangitis and alcohol-related liver disease will be presented at EASL Congress 2024.
May 29, 2024
·
12 min read
1 of 27,456
Next
